Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective

BACKGROUND: Surgical resection has remained the mainstay of treatment of GIST with a 5-year-survival of 28–35%. Tyrosine kinase inhibitor (Imatinib) has revolutionised the treatment of these tumours. The current research is directed towards expanding the role of this drug in the treatment of GIST. W...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Date, Ravindra S, Stylianides, Nicholas A, Pursnani, Kishore G, Ward, Jeremy B, Mughal, Muntzer M
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2008
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2491627/
https://ncbi.nlm.nih.gov/pubmed/18644105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-6-77
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker